Taiwan
· Delayed Price · Currency is TWD Medigen Biotechnology Statistics
Total Valuation
Medigen Biotechnology has a market cap or net worth of TWD 4.84 billion. The enterprise value is 6.80 billion.
| Market Cap | 4.84B |
| Enterprise Value | 6.80B |
Important Dates
The last earnings date was Tuesday, November 12, 2024.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Medigen Biotechnology has 139.31 million shares outstanding. The number of shares has increased by 0.50% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 139.31M |
| Shares Change (YoY) | +0.50% |
| Shares Change (QoQ) | +1.79% |
| Owned by Insiders (%) | 6.56% |
| Owned by Institutions (%) | 4.27% |
| Float | 109.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.44 |
| PB Ratio | 2.93 |
| P/TBV Ratio | 3.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.46 |
| EV / Sales | 4.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -39.35 |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.07 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.68 |
| Interest Coverage | -16.12 |
Financial Efficiency
Return on equity (ROE) is -16.55% and return on invested capital (ROIC) is -6.14%.
| Return on Equity (ROE) | -16.55% |
| Return on Assets (ROA) | -5.66% |
| Return on Capital (ROIC) | -6.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.75 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.68% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -31.68% |
| 50-Day Moving Average | 36.62 |
| 200-Day Moving Average | 39.55 |
| Relative Strength Index (RSI) | 47.07 |
| Average Volume (20 Days) | 132,516 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medigen Biotechnology had revenue of TWD 1.41 billion and -412.89 million in losses. Loss per share was -2.95.
| Revenue | 1.41B |
| Gross Profit | 803.51M |
| Operating Income | -718.27M |
| Pretax Income | -707.92M |
| Net Income | -412.89M |
| EBITDA | -565.97M |
| EBIT | -718.27M |
| Loss Per Share | -2.95 |
Balance Sheet
The company has 2.47 billion in cash and 980.44 million in debt, giving a net cash position of 1.49 billion or 10.69 per share.
| Cash & Cash Equivalents | 2.47B |
| Total Debt | 980.44M |
| Net Cash | 1.49B |
| Net Cash Per Share | 10.69 |
| Equity (Book Value) | 5.13B |
| Book Value Per Share | 11.85 |
| Working Capital | 2.77B |
Cash Flow
In the last 12 months, operating cash flow was -121.99 million and capital expenditures -50.77 million, giving a free cash flow of -172.75 million.
| Operating Cash Flow | -121.99M |
| Capital Expenditures | -50.77M |
| Free Cash Flow | -172.75M |
| FCF Per Share | -1.24 |
Margins
Gross margin is 56.86%, with operating and profit margins of -50.83% and -29.22%.
| Gross Margin | 56.86% |
| Operating Margin | -50.83% |
| Pretax Margin | -50.10% |
| Profit Margin | -29.22% |
| EBITDA Margin | -40.05% |
| EBIT Margin | -50.83% |
| FCF Margin | -12.23% |
Dividends & Yields
Medigen Biotechnology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.50% |
| Shareholder Yield | -0.50% |
| Earnings Yield | -8.50% |
| FCF Yield | -3.57% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |